110 related articles for article (PubMed ID: 21157141)
1. [Late-onset neutropenia following rituximab therapy as a treatment of diffuse large B-cell lymphoma: a single institution study].
Kim M; Lee JK; Hong YJ; Hong SI; Kang HJ; Chang YH
Korean J Lab Med; 2010 Dec; 30(6):575-9. PubMed ID: 21157141
[TBL] [Abstract][Full Text] [Related]
2. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
[TBL] [Abstract][Full Text] [Related]
3. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.
Tesfa D; Palmblad J
Expert Rev Hematol; 2011 Dec; 4(6):619-25. PubMed ID: 22077526
[TBL] [Abstract][Full Text] [Related]
4. Neutropenia associated with rituximab therapy.
Grant C; Wilson WH; Dunleavy K
Curr Opin Hematol; 2011 Jan; 18(1):49-54. PubMed ID: 21102324
[TBL] [Abstract][Full Text] [Related]
5. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy.
Rozman S; Sonc M; Novakovic BJ
Leuk Lymphoma; 2012 Oct; 53(10):1945-8. PubMed ID: 22563814
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center.
Besada E; Koldingsnes W; Nossent J
QJM; 2012 Jun; 105(6):545-50. PubMed ID: 22301823
[TBL] [Abstract][Full Text] [Related]
7. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
Wolach O; Bairey O; Lahav M
Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108
[TBL] [Abstract][Full Text] [Related]
8. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.
Tesfa D; Gelius T; Sander B; Kimby E; Fadeel B; Palmblad J; Hägglund H
Med Oncol; 2008; 25(4):374-9. PubMed ID: 18278570
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.
Arai Y; Yamashita K; Mizugishi K; Nishikori M; Hishizawa M; Kondo T; Kitano T; Kawabata H; Kadowaki N; Takaori-Kondo A
Hematology; 2015 May; 20(4):196-202. PubMed ID: 25130775
[TBL] [Abstract][Full Text] [Related]
10. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.
Nitta E; Izutsu K; Sato T; Ota Y; Takeuchi K; Kamijo A; Takahashi K; Oshima K; Kanda Y; Chiba S; Motokura T; Kurokawa M
Ann Oncol; 2007 Feb; 18(2):364-9. PubMed ID: 17079695
[TBL] [Abstract][Full Text] [Related]
11. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.
Keane C; Nourse JP; Crooks P; Nguyen-Van D; Mutsando H; Mollee P; Lea RA; Gandhi MK
Intern Med J; 2012 Oct; 42(10):1113-9. PubMed ID: 21883784
[TBL] [Abstract][Full Text] [Related]
12. Neutropenia after rituximab treatment: new insights on a late complication.
Wolach O; Shpilberg O; Lahav M
Curr Opin Hematol; 2012 Jan; 19(1):32-8. PubMed ID: 22080846
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.
Li SC; Chen YC; Evens AM; Lee CC; Liao HF; Yu CC; Tung YT; Su YC
Am J Hematol; 2010 Oct; 85(10):810-2. PubMed ID: 20730791
[TBL] [Abstract][Full Text] [Related]
14. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.
Aguiar-Bujanda D; Blanco-Sánchez MJ; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura-Grau S; Bohn-Sarmiento U
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):761-5. PubMed ID: 26319620
[TBL] [Abstract][Full Text] [Related]
15. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
[TBL] [Abstract][Full Text] [Related]
16. Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.
Monaco WE; Jones JD; Rigby WF
Clin Rheumatol; 2016 Oct; 35(10):2457-62. PubMed ID: 27209045
[TBL] [Abstract][Full Text] [Related]
17. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
19. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Nishikawa H; Tsudo M; Osaki Y
Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
